Switching therapy to tenofovir disoproxil fumarate (TDF) is effective
in treatment-resistant chronic hepatitis B, show results from a cohort
of Asian patients.
Administration of TDF resulted in a sustained
virological response in the majority of nucleos(t)ide analogue
(NUC)-experienced patients after nearly 2 years of follow-up, report the
researchers.
But the findings also showed that those with a high
baseline level of hepatitis B virus (HBV) were significantly less likely
to achieve a sustained virological response than patients with lower
baseline levels.
Read more...Labels: Asian patients, resistance, tenofovir disoproxil fumarate (TDF)